Christina Louise Costantino, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonectomy | 2 | 2021 | 1128 | 0.840 |
Why?
|
| Ribs | 1 | 2021 | 254 | 0.640 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2021 | 97 | 0.640 |
Why?
|
| Esophageal Achalasia | 1 | 2020 | 99 | 0.630 |
Why?
|
| Tracheal Neoplasms | 1 | 2018 | 124 | 0.580 |
Why?
|
| Laparoscopy | 2 | 2020 | 2039 | 0.570 |
Why?
|
| Gastrectomy | 3 | 2019 | 694 | 0.570 |
Why?
|
| Stomach Neoplasms | 4 | 2021 | 1471 | 0.540 |
Why?
|
| Trachea | 2 | 2021 | 1085 | 0.530 |
Why?
|
| Laryngectomy | 1 | 2017 | 244 | 0.500 |
Why?
|
| Laryngostenosis | 1 | 2017 | 168 | 0.500 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 639 | 0.450 |
Why?
|
| Tracheostomy | 1 | 2017 | 429 | 0.430 |
Why?
|
| Antigens, Surface | 3 | 2010 | 1617 | 0.360 |
Why?
|
| Deoxycytidine Kinase | 2 | 2010 | 11 | 0.350 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 13451 | 0.340 |
Why?
|
| Deoxycytidine | 2 | 2010 | 889 | 0.300 |
Why?
|
| RNA-Binding Proteins | 3 | 2010 | 1874 | 0.260 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2009 | 1758 | 0.220 |
Why?
|
| General Surgery | 1 | 2015 | 1722 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 6 | 2010 | 5444 | 0.190 |
Why?
|
| Mosaicism | 1 | 2024 | 481 | 0.180 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2024 | 587 | 0.180 |
Why?
|
| Fundoplication | 1 | 2020 | 146 | 0.160 |
Why?
|
| Sexual Harassment | 1 | 2019 | 82 | 0.150 |
Why?
|
| Nitrogen | 1 | 2020 | 346 | 0.150 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2021 | 290 | 0.150 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2009 | 120 | 0.150 |
Why?
|
| Smoking | 1 | 2015 | 9081 | 0.150 |
Why?
|
| Bronchi | 1 | 2021 | 843 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2010 | 647 | 0.140 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2021 | 349 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 1776 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 3537 | 0.130 |
Why?
|
| New Orleans | 1 | 2015 | 27 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2020 | 625 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 5389 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2021 | 65188 | 0.120 |
Why?
|
| Robotics | 1 | 2021 | 809 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 2895 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 1259 | 0.100 |
Why?
|
| Vitamin K 2 | 1 | 2009 | 43 | 0.080 |
Why?
|
| Vitamin K 1 | 1 | 2009 | 41 | 0.080 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 3236 | 0.080 |
Why?
|
| Thymidylate Synthase | 1 | 2009 | 73 | 0.080 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2009 | 66 | 0.080 |
Why?
|
| Immunologic Surveillance | 1 | 2009 | 92 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 1661 | 0.080 |
Why?
|
| Smad4 Protein | 1 | 2009 | 193 | 0.070 |
Why?
|
| Humans | 23 | 2024 | 765968 | 0.070 |
Why?
|
| Education, Medical | 1 | 2019 | 1746 | 0.070 |
Why?
|
| Diphtheria Toxin | 1 | 2008 | 253 | 0.070 |
Why?
|
| Cytarabine | 1 | 2009 | 698 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2015 | 2761 | 0.070 |
Why?
|
| Genome, Human | 1 | 2020 | 4448 | 0.070 |
Why?
|
| Caspases | 1 | 2009 | 880 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2009 | 711 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2009 | 745 | 0.060 |
Why?
|
| Boston | 1 | 2018 | 9338 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2023 | 81514 | 0.060 |
Why?
|
| Time Factors | 3 | 2018 | 40065 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2008 | 963 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2008 | 1500 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2009 | 1648 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2009 | 5337 | 0.050 |
Why?
|
| ras Proteins | 1 | 2009 | 1053 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2009 | 4137 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 8611 | 0.050 |
Why?
|
| Mutation | 4 | 2024 | 30198 | 0.050 |
Why?
|
| Physicians | 1 | 2019 | 4588 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 6113 | 0.050 |
Why?
|
| Adult | 4 | 2021 | 223044 | 0.050 |
Why?
|
| Female | 9 | 2024 | 396112 | 0.050 |
Why?
|
| Middle Aged | 7 | 2024 | 223009 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2010 | 12768 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 2242 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 1534 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2019 | 5946 | 0.040 |
Why?
|
| Alendronate | 1 | 2020 | 174 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 4247 | 0.040 |
Why?
|
| Cell Line, Tumor | 6 | 2010 | 17075 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 3690 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2019 | 170 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2207 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 24282 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 11206 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2008 | 1964 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 4520 | 0.030 |
Why?
|
| Osteoclasts | 1 | 2020 | 713 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15747 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 1884 | 0.030 |
Why?
|
| Aged | 5 | 2024 | 171117 | 0.030 |
Why?
|
| Survival Rate | 2 | 2021 | 12795 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2009 | 3111 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2019 | 477 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10429 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2019 | 1816 | 0.030 |
Why?
|
| Apoptosis | 1 | 2009 | 9514 | 0.030 |
Why?
|
| Lung | 2 | 2023 | 10033 | 0.030 |
Why?
|
| Male | 6 | 2024 | 363698 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 9601 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 74840 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2009 | 11022 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 6364 | 0.020 |
Why?
|
| Recurrence | 1 | 2023 | 8501 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2020 | 2058 | 0.020 |
Why?
|
| Melanoma | 1 | 2009 | 5719 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 5849 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2020 | 2554 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2009 | 186 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2009 | 461 | 0.020 |
Why?
|
| Thymidine | 1 | 2009 | 294 | 0.020 |
Why?
|
| Uridine | 1 | 2009 | 135 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2009 | 157 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2009 | 330 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2009 | 399 | 0.020 |
Why?
|
| Yeasts | 1 | 2009 | 278 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 612 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 472 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 545 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13648 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2009 | 23601 | 0.020 |
Why?
|
| Massachusetts | 1 | 2019 | 8875 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 1644 | 0.020 |
Why?
|
| Length of Stay | 1 | 2019 | 6485 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 3286 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9373 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2010 | 1591 | 0.010 |
Why?
|
| Cadherins | 1 | 2009 | 900 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4562 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2010 | 5020 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 18071 | 0.010 |
Why?
|
| Registries | 1 | 2019 | 8297 | 0.010 |
Why?
|
| RNA Interference | 1 | 2010 | 2832 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 1624 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 20124 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2009 | 2920 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2010 | 4260 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 2887 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 21056 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 1761 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2009 | 3160 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 4108 | 0.010 |
Why?
|
| Cell Survival | 1 | 2009 | 5747 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6069 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 8278 | 0.010 |
Why?
|
| Protein Binding | 1 | 2010 | 9296 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 4772 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 12403 | 0.010 |
Why?
|
| Alleles | 1 | 2009 | 6897 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 10729 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 5786 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 41649 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 7584 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 17594 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 13024 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 5696 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 81819 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 9525 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 9443 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2009 | 7851 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 6942 | 0.000 |
Why?
|
| Animals | 1 | 2020 | 168764 | 0.000 |
Why?
|